טוען...
Lapatinib in the Treatment of Hormone Receptor-Positive/ErbB2-Positive Breast Cancer
SUMMARY: In women with estrogen receptor(ER)- and ErbB2 (HER2)-positive breast cancer, a vicious cycle is established between ER mechanisms of action and the growth factor receptor network, leading to enhanced cell proliferation and endocrine resistance. As such, co-targeting ErbB1 and ErbB2 with la...
שמור ב:
| Main Authors: | , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
S. Karger GmbH
2010
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2931095/ https://ncbi.nlm.nih.gov/pubmed/20847831 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000285775 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|